Invivyd Inc IVVD
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2021-08-06 |
| Shares Out. | 294,610,000 |
| Website | invivyd.com/ ↗ |
| Phone | 13026587581 |
| Employees | 122 |
| Revenue | $13.7M |
| Gross Profit | $12.7M |
| Net Income | -$41.4M |
| Free Cash Flow | -$79.5M |
| Total Assets | $241.7M |
| Total Liabilities | $38.7M |
| Equity | $203.1M |
About Invivyd Inc
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
Invivyd Inc is a publicly traded company under the ticker symbol IVVD on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)